MarginsXMarginsX
Home › Markets › Health Care › CCCC

C4 Therapeutics Inc. (CCCC)

CCCC trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.65
-3.99% on the day
Market cap
$348.0M
Small cap
Revenue · 2025
$35.9M
+1.0% on 2024
Net income · 2025
-$105.0M
-292.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1662579/000162828026012000/0001628280-26-012000-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCCCC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001662579
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$35.9M
Net income-$105.0M
Operating income-$115.2M
Net margin-292.1%
Operating margin-320.5%
Revenue growth+1.0%
Cash$74.6M
Total assets$359.1M
P/E (computed)Net income was not positive
P/S (computed)9.7×

Warning signs

Cash runway
4.9 months
$32.4M cash at September 30, 2026
Share count, 1 year
+35.5%
2025-10-29 to 2026-10-30 · +166.5% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$22K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$32.4M cash; operating cash flow -$19.9M a quarter.Report 2026-09-30
Shares outstanding131,317,488 (2026-10-30); 96,914,418 a year earlier; 49,281,046 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $22K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$8.5M-$21.8M-$26.0M$32.4MNo debt tags$32.3M10-Q 2026-11-05
Q2 2026
2026-06-30
$6.6M-$23.6M-$1.6M$78.6MNo debt tags$35.0M10-Q 2026-08-11
Q1 2026
2026-03-31
$6.2M-$25.1M-$29.9M$61.3MNo debt tags$34.9M10-Q 2026-05-12
Q4 2025
2025-12-31
$11.0M-$20.5M-$22.1M$74.6MNo debt tags$35.9M10-K 2026-02-26
Q3 2025
2025-09-30
$11.2M-$32.2M-$31.2M$58.8MNo debt tags$30.1M10-Q 2026-11-05
Q2 2025
2025-06-30
$6.5M-$26.0M-$12.1M$78.2MNo debt tags$34.2M10-Q 2026-08-11
Q1 2025
2025-03-31
$7.2M-$26.3M-$33.3M$51.3MNo debt tags$39.8M10-Q 2026-05-12
Q4 2024
2024-12-31
$5.2M-$34.6M-$17.9M$55.5MNo debt tags$35.6M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-10
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 552 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-11.0%
1 month-0.7%
3 months-32.4%
Year to date+44.5%
1 year+12.7%
From 52-week high-40.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ALECAlector Inc.$2.57+1.18%$382.6M
PROKProKidney Corp.$1.04-0.48%$314.5M
AUTLAutolus Therapeutics plc American Depositary Share$1.14-2.56%$303.6M
KYTXKyverna Therapeutics Inc.$4.76-5.74%$300.9M
SLBTSL Science Holding Limited$0.7195-3.42%$403.5M
IRLAIRulya Therapeutics Inc.$37.36-6.13%$405.0M
IPSCCentury Therapeutics Inc.$1.64-0.61%$297.8M
TRXBTRex Bio Inc.$10.77-21.21%$295.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier